Skip to main content

APEC1621K APEC1621K NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations.

NCT04195555

APEC1621K NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations.

Associated Conditions

Cancer, Multiple Tumor Types

Principal Investigator

Sponsor

Children's Oncology Group

The main goal is to find out what effect, good and/or bad effects AG-120 (ivosidenib) on your tumor. A second goal of the study is to evaluate side effects that might be caused by AG-120 (ivosidenib), which could shrink your cancer but it could also cause side effects. Also to learn more about the pharmacology and pharmacodynamics (how your body handles the drug, and how the drug affects your body) of AG-120 (ivosidenib).

This study is currently enrolling.